Literature DB >> 20571438

Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose.

Debashis Nandy1, Debabrata Mukhopadhyay, Ananda Basu.   

Abstract

OBJECTIVE: Inadequate vascular remodeling is contributory to increased cardiovascular events in people with type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG). Vascular endothelial growth factor (VEGF) and its regulatory molecule soluble Flt-1(sFlt-1) play important roles in atherogenesis. RESEARCH
DESIGN: We measured fasting plasma concentrations of VEGF and sFlt-1 in 11 nondiabetic (ND) (aged 46.1 +/- 2.1 years; body mass index [BMI], 26.1 +/- 0.9 kg/m; glucose, 5.0 +/- 0.1 mM), 15 IFG (aged 52.9 +/- 1.8 years; BMI, 32.7 +/- 1.3 kg/m; glucose, 6.4 +/- 0.1 mM), and 8 DM (aged 55.8 +/- 3.2 years; BMI, 30.0 +/- 1.0 kg/m; glucose, 9.3 +/- 0.5 mM) subjects.
RESULTS: Plasma VEGF (42.1 +/- 4.0 vs 24.2 +/- 0.9 vs 29.4 +/- 3.8 pg/mL, respectively) and sFlt-1 (119.4 +/- 4.9 vs 58.9 +/- 3.2 vs 56.7 +/- 1.2 pg/mL, respectively) concentrations were higher (P < 0.04) in DM than IFG and ND subjects. Whereas VEGF concentrations were significantly lower (P < 0.05) in IFG than in ND subjects, sFlt-1 concentrations did not differ between the IFG and ND subjects.
CONCLUSIONS: Although plasma VEGF concentrations were higher (35%) in DM than in ND subjects, VEGF action on vascular remodeling was likely attenuated by higher sFlt-1 concentrations in DM. In contrast, IFG subjects did not have major perturbations in either VEGF or sFlt-1 levels. Further studies defining the roles of these mediators in DM and IFG are necessary to extend these observations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571438      PMCID: PMC3677544          DOI: 10.231/JIM.0b013e3181e96203

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  19 in total

Review 1.  Pitfalls in the measurement of circulating vascular endothelial growth factor.

Authors:  W Jelkmann
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy.

Authors:  Nan Hee Kim; Jeong Heon Oh; Ji A Seo; Kye Won Lee; Sin Gon Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Young Sun Kang; Sang Youb Han; Kum Hyun Han; Yi Hwa Ji; Dae Ryong Cha
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

3.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

4.  Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease.

Authors:  Ferdinando Carlo Sasso; Daniele Torella; Ornella Carbonara; Georgina M Ellison; Michele Torella; Michelangelo Scardone; Claudio Marra; Rodolfo Nasti; Raffaele Marfella; Domenico Cozzolino; Ciro Indolfi; Maurizio Cotrufo; Roberto Torella; Teresa Salvatore
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

5.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

Authors:  P L Lip; F Belgore; A D Blann; M W Hope-Ross; J M Gibson; G Y Lip
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

6.  Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis.

Authors:  Hoong Sern Lim; Gregory Y H Lip; Andrew D Blann
Journal:  Atherosclerosis       Date:  2004-12-21       Impact factor: 5.162

7.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.

Authors:  Deepak L Bhatt; P Gabriel Steg; E Magnus Ohman; Alan T Hirsch; Yasuo Ikeda; Jean-Louis Mas; Shinya Goto; Chiau-Suong Liau; Alain J Richard; Joachim Röther; Peter W F Wilson
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

8.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.

Authors:  Andrew D Blann; Funmi M Belgore; Charles N McCollum; Stanley Silverman; Peck Lin Lip; Gregory Y H Lip
Journal:  Clin Sci (Lond)       Date:  2002-02       Impact factor: 6.124

10.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

View more
  9 in total

1.  Alterations in polyadenylation and its implications for endocrine disease.

Authors:  Anders Rehfeld; Mireya Plass; Anders Krogh; Lennart Friis-Hansen
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-08       Impact factor: 5.555

2.  TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis.

Authors:  Chang Xu; Anthony Chang; Bradley K Hack; Michael T Eadon; Seth L Alper; Patrick N Cunningham
Journal:  Kidney Int       Date:  2013-07-31       Impact factor: 10.612

3.  Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome.

Authors:  Witold N Nowak; Sebastian Borys; Katarzyna Kusińska; Karolina Bukowska-Strakova; Przemysław Witek; Teresa Koblik; Alicja Józkowicz; Maciej Tadeusz Małecki; Józef Dulak
Journal:  J Diabetes Investig       Date:  2013-09-06       Impact factor: 4.232

Review 4.  Reduced coronary collateralization in type 2 diabetic patients with chronic total occlusion.

Authors:  Ying Shen; Feng Hua Ding; Yang Dai; Xiao Qun Wang; Rui Yan Zhang; Lin Lu; Wei Feng Shen
Journal:  Cardiovasc Diabetol       Date:  2018-02-08       Impact factor: 9.951

5.  Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis.

Authors:  Mohammad Ishraq Zafar; Kerry Mills; Xiaofeng Ye; Brette Blakely; Jie Min; Wen Kong; Nan Zhang; Luoning Gou; Anita Regmi; Sheng Qing Hu; Juan Zheng; Lu-Lu Chen
Journal:  Diabetol Metab Syndr       Date:  2018-08-03       Impact factor: 3.320

6.  VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes.

Authors:  Reinier O Schlingemann; Cornelis J F Van Noorden; Mattheus J M Diekman; Anna Tiller; Joost C M Meijers; Pieter Koolwijk; Wilmar M Wiersinga
Journal:  Diabetes Care       Date:  2013-01-15       Impact factor: 19.112

Review 7.  Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia.

Authors:  Theresa M Wewers; Annika Schulz; Ingo Nolte; Hermann Pavenstädt; Marcus Brand; Giovana S Di Marco
Journal:  J Am Soc Nephrol       Date:  2021-06-21       Impact factor: 14.978

8.  Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes.

Authors:  Markolf Hanefeld; Katrin Engelmann; Dieter Appelt; Dirk Sandner; Ingo Weigmann; Xenia Ganz; Frank Pistrosch; Carsta Köhler; Antje Gasparic; Andreas L Birkenfeld
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

9.  Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes.

Authors:  Anna Wesołowska; Hanna Winiarska; Jakub Owoc; Magdalena Borowska; Joanna Domagała; Przemysław Łukasz Mikołajczak; Saule Iskakova; Grzegorz Dworacki; Marzena Dworacka
Journal:  Biomolecules       Date:  2021-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.